Arovella Therapeutics Vergangene Ertragsentwicklung
Vergangenheit Kriterienprüfungen 0/6
Arovella Therapeutics's earnings have been declining at an average annual rate of -5.4%, while the Pharmaceuticals industry saw earnings growing at 35.4% annually. Revenues have been growing at an average rate of 15.8% per year.
Wichtige Informationen
-5.4%
Wachstumsrate der Gewinne
49.8%
EPS-Wachstumsrate
| Pharmaceuticals Wachstum der Industrie | 31.2% |
| Wachstumsrate der Einnahmen | 15.8% |
| Eigenkapitalrendite | -77.9% |
| Netto-Marge | -448.0% |
| Letzte Ertragsaktualisierung | 30 Jun 2024 |
Jüngste Aktualisierungen vergangener Leistungen
Aufschlüsselung der Einnahmen und Ausgaben
Wie Arovella Therapeutics Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.
Gewinn- und Umsatzhistorie
| Datum | Einnahmen | Umsatz | Allgemeine und Verwaltungskosten | F&E-Ausgaben |
|---|---|---|---|---|
| 30 Jun 24 | 2 | -9 | 2 | 7 |
| 31 Mar 24 | 2 | -9 | 3 | 6 |
| 31 Dec 23 | 2 | -10 | 3 | 6 |
| 30 Sep 23 | 2 | -10 | 3 | 5 |
| 30 Jun 23 | 1 | -10 | 2 | 4 |
| 31 Mar 23 | 2 | -9 | 2 | 4 |
| 31 Dec 22 | 2 | -9 | 2 | 4 |
| 30 Sep 22 | 1 | -9 | 2 | 3 |
| 30 Jun 22 | 0 | -9 | 2 | 3 |
| 31 Mar 22 | 0 | -8 | 2 | 2 |
| 31 Dec 21 | 1 | -7 | 2 | 1 |
| 30 Sep 21 | 1 | -6 | 2 | 1 |
| 30 Jun 21 | 1 | -5 | 1 | 1 |
| 31 Mar 21 | 1 | -5 | 1 | 0 |
| 31 Dec 20 | 1 | 2 | 1 | 0 |
| 30 Sep 20 | 1 | -1 | 1 | 0 |
| 30 Jun 20 | 1 | -4 | 1 | 0 |
| 31 Mar 20 | 1 | -12 | 2 | 0 |
| 31 Dec 19 | 1 | -15 | 1 | 0 |
| 30 Sep 19 | 1 | -11 | 1 | 0 |
| 30 Jun 19 | 1 | -8 | 1 | 0 |
| 31 Mar 19 | 1 | -6 | 1 | 0 |
| 31 Dec 18 | 1 | -5 | 2 | 0 |
| 30 Sep 18 | 1 | -5 | 2 | 0 |
| 30 Jun 18 | 0 | -6 | 2 | 0 |
| 31 Mar 18 | 5 | -4 | 2 | 0 |
| 31 Dec 17 | 1 | -3 | 2 | 0 |
| 30 Sep 17 | 1 | -2 | 2 | 0 |
| 30 Jun 17 | 1 | -1 | 1 | 0 |
| 31 Mar 17 | 4 | -1 | 2 | 0 |
| 31 Dec 16 | 3 | -1 | 2 | 0 |
| 30 Sep 16 | 5 | -2 | 2 | 0 |
| 30 Jun 16 | 6 | -2 | 3 | 0 |
| 31 Mar 16 | 6 | -3 | 2 | 0 |
| 31 Dec 15 | 6 | -3 | 2 | 0 |
| 30 Sep 15 | 6 | -3 | 2 | 0 |
| 30 Jun 15 | 6 | -3 | 3 | 0 |
| 31 Mar 15 | 6 | -4 | 3 | 0 |
| 31 Dec 14 | 6 | -4 | 3 | 0 |
| 30 Sep 14 | 7 | -3 | 3 | 0 |
| 30 Jun 14 | 9 | -2 | 2 | 0 |
| 31 Mar 14 | 8 | -2 | 2 | 0 |
| 31 Dec 13 | 8 | -1 | 2 | 0 |
Qualität der Erträge: ALA is currently unprofitable.
Wachsende Gewinnspanne: ALA is currently unprofitable.
Analyse von freiem Cashflow und Gewinn
Analyse des Gewinnwachstums in der Vergangenheit
Ergebnisentwicklung: ALA is unprofitable, and losses have increased over the past 5 years at a rate of 5.4% per year.
Beschleunigtes Wachstum: Unable to compare ALA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Erträge im Vergleich zur Industrie: ALA is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (46.5%).
Eigenkapitalrendite
Hohe Eigenkapitalrendite: ALA has a negative Return on Equity (-77.89%), as it is currently unprofitable.